Literature DB >> 18054471

A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer.

C P South1, V S Khoo, O Naismith, A Norman, D P Dearnaley.   

Abstract

AIMS: To compare the radiotherapy planning techniques from two multicentre randomised external beam radiotherapy trials in the UK of conformal radiotherapy vs intensity-modulated radiotherapy (IMRT).
MATERIALS AND METHODS: Sixteen sequential patients with histologically confirmed localised prostate cancer treated in the conventional or hypofractionated IMRT trial (CHHiP) were planned using both the CHHiP and Medical Research Council RT-01 planning protocols to 74 Gy in 37 daily fractions. The CHHiP plan used a single phase simple forward planned three-field IMRT plan for easy multicentre adoption. The RT-01 plan used two phases: three-field conformal radiotherapy plan to 64 Gy followed by a six-field boost of 10 Gy. After coverage of the planning target volumes according to the respective trial protocols, the dose to the rectum and bladder was assessed for the two planning techniques.
RESULTS: There was acceptable planning target volume coverage by both the CHHiP and RT-01 plans. All CHHiP plans produced lower mean irradiated rectal volumes at all measured dose levels compared with the RT-01 plans, particularly for irradiated rectal volumes at 50 and 70 Gy (P<0.05). In the cases when a CHHiP plan failed to meet its own trial dose constraints, the volumes of irradiated rectum were less than if an RT-01 planning technique had been used. The CHHiP plans gave lower mean irradiated bladder volumes at both 50 and 60 Gy, but higher volumes at 74 Gy. These differences in irradiated bladder volumes were significant at the 60 and 74 Gy dose levels (P<0.05) in favour of the CHHiP and RT-01 plans, respectively.
CONCLUSION: The forward planned CHHiP IMRT planning solution gives more favourable rectal sparing than the RT-01 plan. This is important to limit any potential increase in late rectal toxicity for prostate cancer patients treated with high-dose conventional or hypofractionated schedules.

Entities:  

Mesh:

Year:  2007        PMID: 18054471     DOI: 10.1016/j.clon.2007.10.012

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  13 in total

1.  Clinical implementation of volumetric intensity-modulated arc therapy (VMAT) with ERGO++.

Authors:  Dirk Wolff; Florian Stieler; Brigitte Hermann; Katharina Heim; Sven Clausen; Jens Fleckenstein; Martin Polednik; Volker Steil; Frederik Wenz; Frank Lohr
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

Review 2.  Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities).

Authors:  Marigdalia K Ramirez-Fort; Marc J Rogers; Roberto Santiago; Sean S Mahase; Melissa Mendez; Yi Zheng; Xiang Kong; James A Kashanian; M Junaid Niaz; Shearwood McClelland; Xiaodong Wu; Neil H Bander; Peter Schlegel; John P Mulhall; Christopher S Lange
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-19

3.  Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.

Authors:  O F Naismith; C Griffin; I Syndikus; C South; H Mayles; P Mayles; V Khoo; C Scrase; J Graham; S Hassan; E Hall; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2019-06-06       Impact factor: 4.126

4.  Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.

Authors:  Julia Murray; Sarah Gulliford; Clare Griffin; Anna Wilkins; Isabel Syndikus; John Staffurth; Miguel Panades; Christopher Scrase; Chris Parker; Vincent Khoo; Jamie Dean; Helen Mayles; Philip Mayles; Simon Thomas; Olivia Naismith; Helen Mossop; Clare Cruickshank; Emma Hall; David Dearnaley
Journal:  Clin Transl Radiat Oncol       Date:  2019-12-31

5.  Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy - A Voxel-by-Voxel Analysis.

Authors:  Mona Splinter; Ilias Sachpazidis; Tilman Bostel; Tobias Fechter; Constantinos Zamboglou; Christian Thieke; Oliver Jäkel; Peter E Huber; Jürgen Debus; Dimos Baltas; Nils H Nicolay
Journal:  Front Oncol       Date:  2020-09-29       Impact factor: 6.244

6.  Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor.

Authors:  Ratul Mukerji; Jeffrey Schaal; Xinghai Li; Jayanta Bhattacharyya; Daisuke Asai; Michael R Zalutsky; Ashutosh Chilkoti; Wenge Liu
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

7.  A comparison of a moderately hypofractionated IMRT planning technique used in a randomised UK external beam radiotherapy trial with an in-house technique for localised prostate cancer.

Authors:  Ian Gleeson
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-19

8.  In Vivo Validation of Elekta's Clarity Autoscan for Ultrasound-based Intrafraction Motion Estimation of the Prostate During Radiation Therapy.

Authors:  Alexander Grimwood; Helen A McNair; Tuathan P O'Shea; Stephen Gilroy; Karen Thomas; Jeffrey C Bamber; Alison C Tree; Emma J Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-04-16       Impact factor: 7.038

9.  A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.

Authors:  Julia Murray; Clare Griffin; Sarah Gulliford; Isabel Syndikus; John Staffurth; Miguel Panades; Christopher Scrase; Chris Parker; Vincent Khoo; Jamie Dean; Helen Mayles; Philip Mayles; Simon Thomas; Olivia Naismith; Angela Baker; Helen Mossop; Clare Cruickshank; Emma Hall; David Dearnaley
Journal:  Radiother Oncol       Date:  2019-11-22       Impact factor: 6.280

10.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.